Prelude Therapeutics Incorporated (PRLD)
NasdaqGS · USD · Healthcare · Biotechnology
$3.70 (+0.00%) as of
Key statistics
- Market cap
- 295.27M
- Forward P/E
- -6.38
- EPS (TTM)
- -0.7300
- Dividend yield
- 0.00%
- 52-week range
- 1.1730 – 6.8300
- Beta
- 0.96
- Revenue (TTM)
- 22.42M
- Profit margin
- -269.75%
- Analyst target
- $9.20
- Volume
- 9.21k
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Wilmington, DE, United States
- Employees
- 79
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.